Yingcong Chen

Di Chang, Aljaž Božič, Tong Zhang et al.

Finding accurate correspondences among different views is the Achilles' heel of unsupervised Multi-View Stereo (MVS). Existing methods are built upon the assumption that corresponding pixels share similar photometric features. However, multi-view images in real scenarios observe non-Lambertian surfaces and experience occlusions. In this work, we propose a novel approach with neural rendering (RC-MVSNet) to solve such ambiguity issues of correspondences among views. Specifically, we impose a depth rendering consistency loss to constrain the geometry features close to the object surface to alleviate occlusions. Concurrently, we introduce a reference view synthesis loss to generate consistent supervision, even for non-Lambertian surfaces. Extensive experiments on DTU and Tanks\&Temples benchmarks demonstrate that our RC-MVSNet approach achieves state-of-the-art performance over unsupervised MVS frameworks and competitive performance to many supervised methods.The code is released at https://github.com/Boese0601/RC-MVSNet

Yingxue Xu, Zhengyu Zhang, Xiuming Zhang et al.

Pathology foundation models have shown strong retrospective performance, but whether such systems can support clinically relevant use remains unclear. This challenge is particularly important in breast cancer, where pathological assessment serves as the gold standard for diagnosis and guides treatment planning, surgical decision-making and risk stratification across pre-, intra- and post-operative stages. Here we present \textbf{BRAVE}, a breast-adaptive pathology foundation model developed and evaluated using a total resource of 101,638 breast whole-slide images from 32 sources across Asia, Europe and North America. We assessed BRAVE across 34 tasks in 82 cohorts spanning pre-operative biopsy, intra-operative frozen section and post-operative resection, using an evidence chain comprising retrospective benchmarking, clinically challenging scenarios, workflow-oriented clinical impact simulations, prospective observational validation with the thresholds locked in the retrospective cohorts and crossover pathologist-AI interaction studies. Across these settings, BRAVE supported practical roles in the clinical workflow, including safe exclusion of low-risk cases from routine review, AI-assisted second-review rescue of initially missed positives and prioritization of cases for further assessment. In prospective validation across three centres, BRAVE excluded 76.9% of negative biopsy cases (NPV 0.953) and 70.1% of negative frozen-section cases (NPV 0.973), and triaged 78.8% of post-operative subtyping cases as high-confidence clear-cut cases (NPV 1.000). In reader studies, AI assistance improved balanced accuracy from 88.5% to 95.1% (OR 3.14, P<0.001), with better efficiency, confidence and inter-rater agreement. BRAVE-derived scores also independently predicted disease-free survival (adjusted HR 4.79, P<0.001) and overall survival (adjusted HR 8.14, P<0.001).